Maximum tolerated dose and optimal tolerated dose of pegylated liposomal doxorubicin hydrochloride (Doxil) when given in combination with cyclophosphamide (Phase I) At the dose level in which 2 or more patients develop treatment-related toxicity of grade 3 or higher OR require a dose adjustment following the first course of treatment [clinicaltrials_resource:50ede22c749d71e99b1f5ce1fbe5bd8f]
Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Maximum tolerated dose and optimal tolerated dose of pegylated liposomal doxorubicin hydrochloride (Doxil) when given in combination with cyclophosphamide (Phase I) At the dose level in which 2 or more patients develop treatment-related toxicity of grade 3 or higher OR require a dose adjustment following the first course of treatment [clinicaltrials_resource:50ede22c749d71e99b1f5ce1fbe5bd8f]
Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician.
Bio2RDF identifier
50ede22c749d71e99b1f5ce1fbe5bd8f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:50ede22c749d71e99b1f5ce1fbe5bd8f
measure [clinicaltrials_vocabulary:measure]
Maximum tolerated dose and opt ...... ith cyclophosphamide (Phase I)
time frame [clinicaltrials_vocabulary:time-frame]
At the dose level in which 2 o ...... the first course of treatment
description
Patients receive oral cyclopho ...... ion of the treating physician.
identifier
clinicaltrials_resource:50ede22c749d71e99b1f5ce1fbe5bd8f
title
Maximum tolerated dose and opt ...... the first course of treatment
@en
type
label
Maximum tolerated dose and opt ...... de22c749d71e99b1f5ce1fbe5bd8f]
@en